Immunosuppression without immunosuppression? How to be a tolerant individual in a dangerous world

Transplant Infectious Disease

Volumn 1, Issue 1, 1999, Pages 65-75

  Kirk, A D ^a  

^a NAVAL MEDICAL RESEARCH CENTER   (United States)

Author keywords

Costimulation; Danger; Tolerance; Transplantation

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

ALLOTRANSPLANTATION; GRAFT REJECTION; HISTOCOMPATIBILITY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; METHODOLOGY; REVIEW;

GRAFT REJECTION; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, HOMOLOGOUS;

EID: 0033086314     PISSN: 13982273     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3062.1999.10107.x     Document Type: Article

References (94)

1. MEDAWAR PB. Immunity to homologous grafted skin. I. The suppression of cell division in grafts transplanted to immunized animals. Br J Exp Pathol 1946: 27: 9.
2. OWEN RD. Immunogenetic consequences of vascular anastomoses between bovine twins. Science 1945: 102: 400-401.
3. BILLINGHAM RE, BRENT L, MEDAWAR PB. Actively acquired tolerance of foreign cells. Nature (London) 1953: 172: 603-606.
4. MITCHISON NA. Passive transfer of transplantation immunity. Proc R Soc Lond (Biol) 1954: 142: 72.
5. TERASAI PI, CECKA JM. Clinical Transplants 1997. Los Angeles: UCLA Tissue Typing Laboratory, 1998.
6. GABER AO, et al. Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation. Transplantation 1998: 66: 29-37.
7. PIRSCH JD, MILLER J, DEIERHOI MH, VINCENTI F, FILO RS. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997: 63: 977-983.
8. WOODLE ES, et al. A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the Tacrolimus Kidney Transplantation Rescue Study Group. Transplantation 1996: 62: 594-599.
9. KNECHTLE SJ, et al. OKT3 vs. ALG induction therapy in combined pancreas-kidney transplantation. Transplant Proc 1991: 23: 1581-1582.
10. FISHMAN JA, RUBIN RH. Infection in organtransplant recipients. N Engl J Med 1998: 338: 1741-1751.
11. SOLLINGER HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995: 60: 225-232.
12. PENN I. Occurrence of cancers in immunosuppressed organ transplant recipients. In: Clinical Transplants 1994. TERASAKI PI, CECKA JM, eds. Los Angeles: UCLA Tissue Typing Laboratory, 1995: 99-109.
13. DEMARIO MD, LEBOWITZ DN. Lymphomas in the immunocompromised patient. Semin Oncol 1998: 25: 492-502.
14. SIA IG, PAYA CV. Infectious complications following renal transplantation. Surg Clin North Am 1998: 78: 95-112.
15. BALISTRERI WF, BUCUVALAS JC, RYCKMAN FC. The effect of immunosuppression on growth and development. Liver Transpl Surg 1995: 1: 64-73.
16. DESAI P, SILVER JG. Drug-induced gingival enlargements. J Can Dental Assoc 1998: 64: 263-268.
17. DRACHMAN BM, DENOFRIO D, ACKER MA, GALETTA S, LOH E. Cortical blindness secondary to cyclosporine after orthotopic heart transplantation: a case report and review of the literature. J Heart Lung Transplant. 1996: 15: 1158-1164.
18. JINDAL RM, SIDNER RA, MILGROM ML. Post-transplant diabetes mellitus. The role of immunosuppression. Drug Saf 1997: 16: 242-257.
19. KIRK AD, JACOBSON LM, HEISEY DM, FASS NA, SOLLINGER HW, PIRSCH JD. Post-transplant diastolic hypertension: associations with intragraft transforming growth factor-beta, endothelin, and renin transcription. Transplantation 1997: 64: 1716-1720.
20. LUCEY MR. Neurological and psychiatric complications associated with immunosuppression in liver transplantation. Liver Transpl Surg 1995: 1: 39-44.
21. SHAW LM, KAPLAN B, KAUFMAN D. Toxic effects of immunosuppressive drugs: mechanisms and strategies for controlling them. Clin Chem 1996: 42: 1316-1321.
22. FOWLKES BJ, RAMSDELL F. T-cell tolerance. Curr Opin Immunol 1993: 5: 873-879.
23. HEATH V, MASON D, RAMIREZ F, SEDDON B. Homeostatic mechanisms in the control of autoimmunity. Semin Immunol 1997: 9: 375-380.
24. LAFFERTY KJ, GAZDA LS. Tolerance: a case of self/not-self discrimination maintained by clonal deletion? Hum Immunol 1997: 52: 119-126.
25. GOODNOW CC. Balancing immunity and tolerance: deleting and tuning lymphocyte repertoires. Proc Natl Acad Sci USA 1996: 93: 2264-2271.
26. MARRACK P, KAPPLER J. T cell tolerance. Semin Immunol 1990: 2: 45-49.
27. MATZINGER P. An innate sense of danger. Semin Immunol 1998: 10: 399-415.
28. RIDGE JP, FUCHS EJ, MATZINGER P. Neonatal tolerance revisited: turning on newborn T cells with dendritic cells. Science 1996: 271: 1723-1726.
29. MATZINGER P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994: 12: 991-1045.
30. BARNES MJ, KNIGHT CG, FARNDALE RW. The collagen-platelet interaction. Curr Opin Hematol 1998: 5: 314-320.
31. GAWAZ M, et al. Activated platelets induce monocyte chemotactic protein-1 secretion and surface expression of intercellular adhesion molecule-1 on endothelial cells. Circulation 1998: 98: 1164-1171.
32. MASSBERG S, et al. Platelet-endothelial cell interactions during ischemia/reperfusion: the role of P-selectin. Blood 1998: 92: 507-515.
33. GEAR AR, SIMON CG, POLANOWSKA-GRABOWSKA R. Platelet adhesion to collagen activates a phosphoprotein complex of heat-shock proteins and protein phosphatase 1. J Neural Transm 1997: 104: 1037-1047.
34. HENN V, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature (London) 1998: 391: 591-594.
35. WEYRICH AS, et al. Activated platelets signal chemokine synthesis by human monocytes. J Clin Invest 1996: 97: 1525-1534.
36. KATO T, YAMANE H, NARIUCHI H. Differential effects of LPS and CD40 ligand stimulations on the induction of IL-12 production by dendritic cells and macrophages. Cell Immunol 1997: 181: 59-67.
37. BUELENS C, VERHASSELT V, DE GROOTE D, THIELEMANS K, GOLDMAN M, WILLEMS F. Human dendritic cell responses to lipopolysaccharide and CD40 ligation are differentially regulated by interleukin-10. Eur J Immunol 1997: 27: 1848-1852.
38. VAN KOOTEN C, BANCHEREAU J. Functions of CD40 on B cells, dendritic cells and other cells. Curr Opin Immunol 1997: 9: 330-337.
39. LU L, et al. Induction of nitric oxide synthase in mouse dendritic cells by IFN-gamma, endotoxin, and interaction with allogeneic T cells: nitric oxide production is associated with dendritic cell apoptosis. J Immunol 1996: 157: 3577-3586.
40. CELLA M, SCHEIDEGGER D, PALMER-LEHMANN K, LANE P, LANZAVECCHIA A, ALBER G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 1996: 184: 747-752.
41. CAUX C, et al. Activation of human dendritic cells through CD40 cross-linking. J Exp Med 1994: 180: 1263-1272.
42. KIM HS, ZHANG X, CHOI YS. Activation and proliferation of follicular dendritic cell-like cells by activated T lymphocytes. J Immunol 1994: 153: 2951-2961.
43. DECHANET J, et al. CD40 ligand stimulates proinflammatory cytokine production by human endothelial cells. J Immunol 1997: 159: 5640-5647.
44. JUNE CH, BLUESTONE JA, NADLER LM, THOMPSON CB. The B7 and CD28 receptor families. Immunol Today 1994: 15: 321-331.
45. GREWAL IS, FLAVELL RA. The role of CD40 ligand in costimulation and T-cell activation. Immunol Rev 1996: 153: 85-106.
46. LENSCHOW DJ, WALUNAS TL, BLUESTONE JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996: 14: 233-258.
47. BLAIR PJ, et al. CTLA-4 ligation delivers a unique signal to resting human CD4 T cells that inhibits interleukin-2 secretion but allows Bcl-XL induction. J Immunol 1998: 160: 12-15.
48. BOISE LH, et al. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity 1995: 3: 87-98.
49. PERRIN PJ, MALDONADO JH, DAVIS TA, JUNE CH, RACKE MK. CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis. J Immunol 1996: 157: 1333-1336.
50. BLUESTONE JA. Is CTLA-4 a master switch for peripheral T cell tolerance? J Immunol 1997: 158: 1989-1993.
51. ALEGRE ML, SHIELS H, THOMPSON CB, GAJEWSKI TF. Expression and function of CTLA-4 in Th1 and Th2 cells. J Immunol 1998: 161: 3347-3356.
52. LIN H, RATHMELL JC, GRAY GS, THOMPSON CB, LEIDEN JM, ALEGRE ML. Cytotoxic T lymphocyte antigen 4 (CTLA4) blockade accelerates the acute rejection of cardiac allografts in CD28-deficient mice: CTLA4 can function independently of CD28. J Exp Med 1998: 188: 199-204.
53. THOMPSON CB, ALLISON JP. The emerging role of CTLA-4 as an immune attenuator. Immunity 1997: 7: 445-450.
54. PEREZ VL, VAN PARIJS L, BIUCKIANS A, ZHENG XX, STROM TB, ABBAS AK. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity 1997: 6: 411-117.
55. WATERHOUSE P, MARENGERE LE, MITTRUCKER HW, MAK TW. CTLA-4, a negative regulator of T-lymphocyte activation. Immunol Rev 1996: 153: 183-207.
56. WATERHOUSE P, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995: 270: 985-988.
57. TOES RM, SCHOENBERGER SP, VAN DER VOORT EH, OFFRINGA R MELIEF CM. CD40-CD40Ligand interactions and their role in cytotoxic T lymphocyte priming and anti-tumor immunity. Semin Immunol 1998: 10: 443-448.
58. SCHOENBERGER SP, TOES RE, VAN DER VOORT EI, OFFRINGA R MELIEF CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature (London) 1998: 393: 480-483.
59. BENNETT SR, CARBONE FR, KARAMALIS F, FLAVELL RA, MILLER JF, HEATH WR. Help for cytotoxic-T-cell responses is mediated by CD40 signaling. Nature (London) 1998: 393: 478-480.
60. RITTER K, FUDICKAR A, HEINE N, THOMSSEN R. Autoantibodies with a protective function: polyreactive antibodies against alkaline phosphatase in bacterial infections. Med Microbiol Immunol (Berlin) 1997: 186: 109-113.
61. PARKER W, YU PB, HOLZKNECHT ZE, LUNDBERG K, BUCKLEY RH, PLATT JL. Specificity and function of "natural" antibodies in immunodeficient subjects: clues to B cell lineage and development. J Clin Immunol 1997: 17: 311-321.
62. CASALI P, SCHETTINO EW. Structure and function of natural antibodies. Curr Topics Microbiol Immunol 1996: 210: 167-179.
63. ROAKE JA, RAO AS, MORRIS PJ, LARSEN CP, HANKINS DF, AUSTYN JM. Systemic lipopolysaccharide recruits dendritic cell progenitors to nonlymphoid tissues. Transplantation 1995: 59: 1319-1324.
64. DEMPSEY PW, FEARON DT. Complement: instructing the acquired immune system through the CD21/CD19 complex. Res Immunol 1996: 147: 71-75.
65. DEMPSEY PW, ALLISON ME, AKKARAJU S, GOODNOW CC, FEARON DT. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 1996: 271: 348-350.
66. FEARON DT. The complement system and adaptive immunity. Semin Immunol 1998: 10: 355-361.
67. ANDRE I, GONZALEZ A, WANG B, KATZ J. BENOIST C, MATHIS D. Checkpoints in the progression of autoimmune disease: lessons from diabetes models. Proc Natl Acad Sci USA 1996: 93: 2260-2263.
68. LOHSE AW. Autoreactive T cells. Curr Opin Immunol 1989: 1: 718-726.
69. LARSEN CP, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature (London) 1996: 381: 434-438.
70. LARSEN CP, PEARSON TC. The CD40 pathway in allograft rejection, acceptance, and tolerance. Curr Opin Immunol 1997: 9: 641-647.
71. KIRK AD, et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA 1997: 94: 8789-8794.
72. LARSEN CP, et al. CD40-gp39 interactions play a critical role during allograft rejection. Suppression of allograft rejection by blockade of the CD40-gp39 pathway. Transplantation 1996: 61: 4-9.
73. LAKKIS FG, et al. Blocking the CD28-B7 T cell costimulation pathway induces long term cardiac allograft acceptance in the absence of IL-4. J Immunol 1997: 158: 2443-2448.
74. PEARSON TC, et al. Analysis of the B7 costimulatory pathway in allograft rejection. Transplantation 1997: 63: 1463-1469.
75. PEARSON TC, ALEXANDER DZ, WINN KJ, LINSLEY PS, LOWRY RP, LARSEN CP. Transplantation tolerance induced by CTLA4-Ig. Transplantation 1994: 57: 1701-1706.
76. JONKER M, et al. Induction of kidney graft acceptance by creating a window of opportunity for immunologic engagement (WOFIE) in rhesus monkeys. Transplant Proc 1998: 30: 2441-2443.
77. JONKER M, et al. Complete withdrawal of immunosuppression in kidney allograft recipients: a prospective study in rhesus monkeys. Transplant Proc 1998: 30: 2451-2453.
78. LEONARD AA, JONKER M, LAGAAIJ EL. Complete withdrawal of immunosuppression in allograft recipients. A study in rhesus monkeys. Transplantation 1996: 61: 1648-1651.
79. GOTOH M, et al. Tolerance induction by liver grafting and FK 506 treatment in nonhuman primates. Transplant Proc 1991: 23: 3265-3268.
80. BURLINGHAM WJ, et al. Microchimerism linked to cytotoxic T lymphocyte functional unresponsiveness (clonal anergy) in a tolerant renal transplant recipient. Transplantation 1995: 59: 1147-1155.
81. MAZARIEGOS GV, et al. Weaning of immunosuppression in liver transplant recipients. Transplantation 1997: 63: 243-249.
82. WONG T, NOURI-ARIA KT, DEVLIN J. PORTMANN B, WILLIAMS R. Tolerance and latent cellular rejection in long-term liver transplant recipients. Hepatology 1998: 28: 443-449.
83. TZAKIS AG, et al. Early tolerance in pediatric liver allograft recipients. J Pediatr Surg 1994: 29: 754-756.
84. CHRISTENSEN LL, GRUNNET N, RUDIGER N, MOLLER B, BIRKELAND SA. Indications of immunological tolerance in kidney transplantation. Tissue Antigens 1998: 51: 637-644.
85. YOUNG AJ, HAY JB, MACKAY CR. Lymphocyte recirculation and life span in vivo. Curr Topics Microbiol Immunol 1993: 184: 161-173.
86. STEKEL DJ, PARKER CE, NOWAK MA. A model of lymphocyte recirculation. Immunol Today 1997: 18: 216-221.
87. BRADLEY LM, WATSON SR. Lymphocyte migration into tissue: the paradigm derived from CD4 subsets. Curr Opin Immunol 1996: 8: 312-320.
88. JANEWAY CAJ, GOODNOW CC, MEDZHITOV R. Danger - pathogen on the premises! Immunological tolerance. Curr Biol 1996: 6: 519-522.
89. FEARON DT, LOCKSLEY RM. The instructive role of innate immunity in the acquired immune response. Science 1996: 272: 50-53.
90. JANEWAY CAJ. The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol Today 1992: 13: 11-16.
91. JANEWAY CAJ. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harbor Symp Quant Biol 1989: 54: 1-13.
92. HASSAN-WALKER AF, COPE AV, GRIFFITHS PD, EMERY VC. Transcription of the human cytomegalovirus natural killer decoy gene, UL18, in vitro and in vivo. J Gen Virol 1998: 79: 2113-2116.
93. LEONG CC, et al. Modulation of natural killer cell cytotoxicity in human cytomegalovirus infection: the role of endogenous class I major histocompatibility complex and a viral class I homolog. J Exp Med 1998: 187: 1681-1687.
94. BROWNE H, CHURCHER M, MINSON T. Construction and characterization of a human cytomegalovirus mutant with the UL18 (class I homolog) gene deleted. J Virol 1992: 66: 6784-6787.